Norepinephrine Infusion Dosing
Start norepinephrine at 2-3 mL/min (8-12 mcg/min) of a standard dilution (4 mcg/mL), then titrate to maintain a mean arterial pressure (MAP) of 65 mmHg, with typical maintenance doses ranging from 2-4 mcg/min (0.5-1 mL/min). 1
Initial Dosing and Preparation
The FDA-approved dosing protocol is straightforward 1:
- Standard dilution: Add 4 mg norepinephrine to 1000 mL of 5% dextrose solution, creating a 4 mcg/mL concentration
- Starting rate: 2-3 mL/min (equivalent to 8-12 mcg/min of base)
- Maintenance range: 0.5-1 mL/min (2-4 mcg/min of base)
Critical preparation note: Norepinephrine must be diluted in dextrose-containing solutions (5% dextrose or 5% dextrose with saline) to prevent oxidation and loss of potency. Saline alone is not recommended 1.
Target Blood Pressure
The Surviving Sepsis Campaign guidelines provide clear direction 2, 3:
- Primary MAP target: 65 mmHg (strong recommendation, moderate quality evidence)
- For previously hypertensive patients: Raise blood pressure no higher than 40 mmHg below their baseline systolic pressure 1
A multicenter trial comparing MAP targets of 65 mmHg versus 85 mmHg found no mortality difference (36.6% vs 34.0% at 28 days), but the higher target increased arrhythmia risk. The only benefit of higher MAP was reduced need for renal replacement therapy in patients with chronic hypertension 3.
Weight-Based Dosing Considerations
While the FDA label provides non-weight-based dosing, clinical practice often uses weight-based calculations:
- Low dose: <0.2 mcg/kg/min
- Intermediate dose: 0.2-0.4 mcg/kg/min
- High dose: >0.4 mcg/kg/min
These cutoffs correlate with increasing mortality (14.0%, 26.4%, and 40.2% respectively) 4.
Important caveat for obese patients: Obese patients require lower weight-based doses than non-obese patients (0.09 vs 0.13 mcg/kg/min) but similar total doses (9 vs 8 mcg/min), suggesting actual body weight dosing may lead to overdosing in obesity 5.
High-Dose Scenarios
When standard doses fail to achieve adequate MAP 1:
- Doses may need to be substantially increased—occasionally up to 68 mg/day (17 vials) have been required
- Critical pitfall: Before escalating to high doses, always suspect and correct occult blood volume depletion
- Central venous pressure monitoring helps detect hypovolemia in refractory hypotension
Administration Route and Safety
Preferred access 1:
- Large vein, particularly antecubital or external jugular
- Avoid leg veins in elderly patients or those with vascular disease (risk of gangrene)
- Central line placement recommended as soon as practical 2
Peripheral administration: A protocol allowing peripheral norepinephrine (≤20 mcg/min through ≥18 gauge IV at or above antecubital fossa) showed only 4.5% extravasation rate with no extremity injury 6, making peripheral administration acceptable when central access is delayed.
Titration Strategy
The Surviving Sepsis Campaign establishes norepinephrine as the first-choice vasopressor (strong recommendation, moderate quality evidence) 2:
- Titrate to MAP 65 mmHg as initial target
- Add vasopressin (0.03 units/min) or epinephrine if additional agent needed to maintain MAP
- Avoid dopamine except in highly selected patients with low arrhythmia risk and bradycardia
Key Clinical Pitfalls
- Volume status first: Always correct hypovolemia before or concurrent with vasopressor initiation 1
- Extravasation monitoring: Check infusion site frequently; blanching along the vein may indicate vasa vasorum constriction even without obvious extravasation 1
- Drug interactions: Use extreme caution with MAO inhibitors or tricyclic antidepressants (risk of severe, prolonged hypertension) 1
- Avoid cyclopropane/halothane anesthesia: Risk of ventricular arrhythmias 1